{
    "items": [
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-listed-in-the-naugural-edition-of-the-sunday-times-100-tech-2025\" title=\"Enara Bio listed in the inaugural edition of The Sunday Times 100 Tech 2025\" class=\"state-published\">Enara Bio listed in the inaugural edition of The Sunday Times 100 Tech 2025</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">22 January 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">The guide showcases Britain's fastest-growing private tech companies from The Sunday Times, commercialising innovation across the UK.\r\n\r\n\"This recognition is a testament to our innovative science and the hard work of our incredible team as we strive to develop safe and effective treatments for cancer patients.\" Enara Bio</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/u-ploid-biotechnologies-announces-the-appointment-of-professor-alison-campbell-to-its-advisory-board\" title=\"U-Ploid Biotechnologies announces the appointment of Professor Alison Campbell to its advisory board\" class=\"state-published\">U-Ploid Biotechnologies announces the appointment of Professor Alison Campbell to its advisory board</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">15 January 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">U-Ploid, a venture-backed biotechnology company developing next-generation fertility therapeutics, is pleased to announce the appointment of Professor Alison Campbell to its Advisory Board. In this key role, Professor Campbell will provide strategic guidance on company research programmes, working closely with the U-Ploid team to drive innovation in fertility treatments.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/oxford-cancer-analytics-raises-usd-11m-in-series-a-funding-to-transform-early-lung-cancer-detection-and-enable-curative-treatments\" title=\"Oxford Cancer Analytics raises USD$11M in series A funding to  transform early lung cancer detection and enable curative treatments\" class=\"state-published\">Oxford Cancer Analytics raises USD$11M in series A funding to  transform early lung cancer detection and enable curative treatments</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">9 January 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Dr. Heinrich Roder, expert in lung cancer proteomics liquid biopsy, appointed as Senior Vice President of Research and Development at OXcan.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/alchemab-therapeutics-enters-into-collaboration-with-lilly-to-discover-research-and-develop-novel-therapies-for-als\" title=\"Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS\" class=\"state-published\">Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">9 January 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">The agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-appoints-david-apelian-md-phd-mba-as-ceo\" title=\"Theolytics appoints David Apelian MD, PhD, MBA as CEO\" class=\"state-published\">Theolytics appoints David Apelian MD, PhD, MBA as CEO</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">17 December 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics. Dr Apelian joins as the company advances its first clinical trial with lead candidate THEO-260 in ovarian cancer.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/alethiomics-2013-using-artermis-to-hunt-down-blood-cancers\" title=\"Alethiomics \u2013 using Artemis to hunt down blood cancers\" class=\"state-published\">Alethiomics \u2013 using Artemis to hunt down blood cancers</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=company-insights\" title=\"Company insights\">\n\t\t                <span class=\"label label-primary\">Company insights</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">12 December 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Spin-out company Alethiomics, focused on the development of innovative treatments for blood cancers, is Oxford through-and-through. Founded by Clinician Scientists who run neighbouring laboratories at the University\u2019s MRC Weatherall Institute of Molecular Medicine, seed financed by Oxford Science Enterprises and located at the BioEscalator, the company\u2019s early years have been immersed in the Oxford innovation ecosystem.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/bioescalator-bulletin-winter-2024\" title=\"BioEscalator Bulletin - Winter 2024\" class=\"state-published\">BioEscalator Bulletin - Winter 2024</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=bioescalator-bulletin\" title=\"BioEscalator bulletin\">\n\t\t                <span class=\"label label-primary\">BioEscalator bulletin</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">11 December 2024</p>\n            \n                            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-strengthens-its-leadership-team-with-the-promotions-of-hsin-loke-to-chief-operating-officer-and-jon-roffey-to-senior-vice-president-discovery-and-non-clinical\" title=\"OMass Therapeutics strengthens its leadership team with the promotions of Hsin Loke to Chief Operating officer and Jon Roffey to Senior Vice President, Discovery and Non-Clinical\" class=\"state-published\">OMass Therapeutics strengthens its leadership team with the promotions of Hsin Loke to Chief Operating officer and Jon Roffey to Senior Vice President, Discovery and Non-Clinical</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">6 December 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that the Company has promoted Dr Hsin Loke to Chief Operating Officer (COO) and Jon Roffey Ph.D. to Senior Vice President, Discovery and Non-Clinical, effective immediately.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/ai-powered-cancer-immunotherapy-discovery-could-be-a-step-closer\" title=\"AI-powered cancer immunotherapy discovery could be a step closer\" class=\"state-published\">AI-powered cancer immunotherapy discovery could be a step closer</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">28 November 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">TechBio startup, Exogene, is leveraging artificial intelligence (AI) to develop innovative immunotherapies with the potential to eliminate untreatable solid tumours in cancer patients. Through a collaboration with German company Alithea Bio, Exogene hopes to speed up cancer immunotherapy discovery and make it more cost-effective.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-doses-first-patient-in-phase-i-iia-trial-of-theo-260-in-ovarian-cancer\" title=\"Theolytics doses first patient in Phase I/IIa Trial of THEO-260 in ovarian cancer\" class=\"state-published\">Theolytics doses first patient in Phase I/IIa Trial of THEO-260 in ovarian cancer</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">19 November 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first patient in its Phase I/IIa multi-centre, open-label first-in-human trial (OCTOPOD - NCT06618235) of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer (PROC).</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-appoints-professor-steven-charlton-as-chief-scientific-officer\" title=\"OMass Therapeutics appoints Professor Steven Charlton as Chief Scientific Officer\" class=\"state-published\">OMass Therapeutics appoints Professor Steven Charlton as Chief Scientific Officer</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">15 November 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Professor Steven Charlton as Chief Scientific Officer (CSO), effective 1 December 2024. He will take on the role from Dr Ali Jazayeri, who is leaving OMass to pursue other opportunities.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/exogene-could-be-a-step-closer-to-ai-powered-immunotherapy-discovery\" title=\"Exogene could be a step closer to AI-powered immunotherapy discovery\" class=\"state-published\">Exogene could be a step closer to AI-powered immunotherapy discovery</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">11 November 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Through UK-Germany Collaborative R&amp;D funding, Exogene is collaborating with the German company Alithea Bio, aiming to accelerate cancer immunotherapy discovery and make it more cost-effective.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/cyanocapture-at-the-forefront-h2boost-deployment-and-cosec-horizon-grant-to-scale-biogenic-co2-capture\" title=\"CyanoCapture at the forefront: H2Boost deployment and COSEC Horizon grant to scale biogenic CO2 capture\" class=\"state-published\">CyanoCapture at the forefront: H2Boost deployment and COSEC Horizon grant to scale biogenic CO2 capture</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">10 November 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">CyanoCapture is making significant strides in advancing sustainable carbon capture technologies with its involvement in two major projects. Both initiatives highlight CyanoCapture's commitment to pioneering carbon-negative solutions and driving progress toward a sustainable, low-carbon future.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/infinitopes-to-showcase-breakthroughs-on-cancer-vaccine-development-at-sitc-2024-insight-into-a-double-blind-phase-i-iia-clinical-trial\" title=\"Infinitopes to showcase breakthroughs on cancer vaccine development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial\" class=\"state-published\">Infinitopes to showcase breakthroughs on cancer vaccine development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">8 November 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Infinitopes, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announces that it will be presenting three posters on its pioneering cancer vaccine discovery and development, including one that has been recognised as a \u2018top 100\u2019 poster presentation, at the Society for Immunotherapy of Cancer (SITC) 2024, held in Houston, US, from 6-10th November.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/leading-academics-and-innovators-join-refreshed-bioescalator-management-board\" title=\"Leading academics and innovators join refreshed BioEscalator Management Board\" class=\"state-published\">Leading academics and innovators join refreshed BioEscalator Management Board</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=bioescalator-news\" title=\"BioEscalator news\">\n\t\t                <span class=\"label label-primary\">BioEscalator news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">30 October 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">In its first major refresh since its establishment in 2018, the BioEscalator is delighted to welcome five leading University of Oxford academics and innovators to its Management Board. Professors Catherine Green OBE, Beth Psaila, Molly Stevens DBE, Krina Zondervan and Peter Callow, Financial Controller of the Medical Sciences Division at the University of Oxford. The Management Board provides a source of expertise for BioEscalator tenants and works to enhance research at the University by building strong links with small life sciences companies.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/nucleome-therapeutics-announces-a-strategic-collaboration-with-johnson-johnson-to-map-genetic-associations-linked-to-autoimmune-disease\" title=\"Nucleome Therapeutics announces a strategic collaboration with Johnson &amp; Johnson to map genetic associations linked to autoimmune disease\" class=\"state-published\">Nucleome Therapeutics announces a strategic collaboration with Johnson &amp; Johnson to map genetic associations linked to autoimmune disease</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">21 October 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Nucleome Therapeutics (\u2018Nucleome\u2019 or \u2018the Company\u2019), a biotechnology company using 3D genomics to discover precision medicines for complex diseases, announces today it has entered a research collaboration with Johnson &amp; Johnson*.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/internationally-renowned-academic-lee-sweetlove-joins-moa\" title=\"Internationally renowned academic Lee Sweetlove joins Moa\" class=\"state-published\">Internationally renowned academic Lee Sweetlove joins Moa</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">15 October 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Moa Technology is pleased to announce that Lee Sweetlove, Professor of Plant Sciences at the University of Oxford, has joined our team. Professor Sweetlove will be working to further understanding of the novel herbicidal modes of action discovered by Moa, which we are currently developing into safe, effective and affordable solutions to protect harvests from crop-killing weeds.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa2019s-ground-breaking-science-features-in-journal-weed-science\" title=\"Moa\u2019s groundbreaking science features in journal Weed Science\" class=\"state-published\">Moa\u2019s groundbreaking science features in journal Weed Science</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">9 October 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Breaking the 30 year impasse in novel herbicide discovery.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/a-plant-sciences-spin-out-flourishes-at-the-bioescalator\" title=\"A plant sciences spin-out flourishes at the BioEscalator\" class=\"state-published\">A plant sciences spin-out flourishes at the BioEscalator</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=company-insights\" title=\"Company insights\">\n\t\t                <span class=\"label label-primary\">Company insights</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">2 October 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">\u2018Mighty oaks from little acorns grow.\u2019 And so it is with novel herbicide developer Moa Technology, which has grown from four people when it first became a BioEscalator tenant to a company of 85 with research facilities in Oxford and Yorkshire.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-raises-32-5-million-series-b-financing-to-advance-first-in-class-pipeline-of-tcr-based-immunotherapies-targeting-novel-dark-antigens\" title=\"Enara Bio raises $32.5M Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens\u00ae\" class=\"state-published\">Enara Bio raises $32.5M Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens\u00ae</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">2 October 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Enara Bio today announces the closing of a $32.5M Series B financing supported by a strong syndicate of new and existing biotech investors. The round was co-led by new investors, Pfizer Ventures and M Ventures, with participation from all existing investors, including RA Capital, Samsara BioCapital and SV Health Investors.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n"
    ], 
    "more": "\n\n    \n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/bioarchitech-graduates-from-the-bioescalator-a-new-chapter-for-innovative-cancer-therapy/search?db453715-1a9f-11f1-be65-c7bc867cde1e=&amp;b_start:int=120&amp;tab=newsitem&amp;format=json&amp;random=2f0a71f4-7dbe-4abf-a9f3-4c54b063cf94\" title=\"Load more\" class=\"btn btn-default load-more-button\">\n            Load More\n        </a>\n    \n\n", 
    "msg": ""
}